Juvenile Amyotrophic Lateral Sclerosis (JALS): Comprehensive Research Report

1. Disease Information

Overview

Juvenile amyotrophic lateral sclerosis (JALS) is a clinically and genetically heterogeneous group of motor neuron disorders defined operationally by symptom onset before age 25 years, involving progressive degeneration of both upper motor neurons (UMN, corticospinal tract) and lower motor neurons (LMN, anterior horn cells/bulbar nuclei). It is distinguished from adult-onset ALS (AO-ALS) by three major features, as summarized in the principal review of the field: 1. A markedly higher genetic yield — ~40% of JALS cases have an identifiable causative gene mutation, versus ~10% of AO-ALS cases 2. A highly variable disease course, "from very aggressive to a more indolent" trajectory, in contrast to the relatively uniform ~2–3 year mortality of typical AO-ALS 3. A greater propensity for syndromic, multi-system neurodegeneration extending beyond the motor system (cognitive, cerebellar, sensory, or movement-disorder features), whereas AO-ALS is comparatively restricted to motor pathways (Ghasemi & Brown/JALS review, Genes 2021, PMID: 34946884)

Key Identifiers

Table (click to expand)

Resource	Identifier
MONDO	MONDO:0017593
Orphanet	ORPHA:300605 (Juvenile amyotrophic lateral sclerosis); related: ORPHA:247604 (Juvenile primary lateral sclerosis); ORPHA:357043 (ALS type 4)
OMIM	#205100 (ALS2, juvenile ALS due to ALS2/alsin); #602433 (ALS4, SETX); #105400 (ALS1 umbrella entry, SOD1)
GARD (NIH)	GARD:11901

Synonyms / Alternative Names

Juvenile-onset amyotrophic lateral sclerosis (jALS)
Early-onset ALS
Pediatric ALS
Gene-specific eponymous forms: ALS2 (juvenile ALS-2), ALS4 (SETX/senataxin-related juvenile ALS), ALS16 (SIGMAR1-related)
Overlapping allelic disorders at the ALS2 locus: infantile-onset ascending hereditary spastic paralysis (IAHSP), juvenile primary lateral sclerosis (JPLS)

Data provenance

Nearly all quantitative epidemiologic data on JALS derive from aggregated, registry- or literature-level sources — principally the US CDC National ALS Registry (44 confirmed/likely juvenile cases identified 2010–2018) and pooled case-series/case-report literature reviews — rather than large prospective individual-patient cohorts, reflecting the disease's rarity (Larkin et al., Amyotroph Lateral Scler Frontotemporal Degener 2023, PMID: 37789566).

2. Etiology

Disease Causal Factors

JALS is primarily a monogenic/oligogenic disorder in the ~40% of cases with an identified mutation; the remainder are presumed sporadic/idiopathic or due to as-yet-unidentified genetic causes. Fifteen genes have been reported in association with JALS, though only three — FUS, SETX, and ALS2 — are recurrently implicated across multiple independent families, with the rest supported by single or few case reports (PMID: 34946884).

Genetic Risk/Causal Factors (by gene; see Section 4 for full detail)

FUS (fused in sarcoma) — most frequently implicated gene in JALS; predominantly de novo mutations
SETX (senataxin) — the only recurrent autosomal dominant JALS gene (ALS4)
ALS2 (alsin) — autosomal recessive; historically enriched in North African/Middle Eastern consanguineous families
SIGMAR1 (sigma-1 receptor) — autosomal recessive, very early (infantile) onset
SOD1 — rare in JALS (3 reported cases), typically de novo, distinct mutation spectrum from AO-ALS SOD1
SPTLC1 — mostly de novo; one autosomal dominant family
SPG11 — autosomal recessive
UBQLN2 — X-linked dominant
ERLIN1, GNE, TARDBP, VRK1, SYNE1, BICD2, DDHD1 — single-family/case reports (PMID: 34946884)

Environmental Risk Factors

No well-established environmental or occupational risk factors specific to JALS have been identified in the literature reviewed; environmental risk factor research in ALS overall (e.g., military service, heavy metal exposure, smoking, physical trauma) is concentrated in adult-onset, largely sporadic disease and has not been systematically studied in the pediatric/juvenile population. This is a notable evidence gap.

Protective Factors

No specific genetic or environmental protective factors for JALS are documented in the literature surveyed. General population variant-frequency data (e.g., gnomAD) for the causal genes have not been reported as conferring disease protection.

Gene–Environment Interactions

Not established for JALS specifically; the disease is modeled overwhelmingly as monogenic with variable expressivity/penetrance (e.g., SETX-ALS4 shows sex-dependent penetrance — see Section 9) rather than as a gene–environment interaction disorder.

3. Phenotypes

Core Motor Phenotype

Progressive muscle weakness and atrophy (LMN sign) — HPO: HP:0003324 (Generalized muscle weakness) / HP:0007358 (Progressive muscle weakness); HP:0003202 (Skeletal muscle atrophy)
Spasticity, hyperreflexia, extensor plantar responses (UMN signs) — HPO: HP:0001257 (Spasticity), HP:0001347 (Hyperreflexia), HP:0003487 (Babinski sign)
Fasciculations — HPO: HP:0002380
Dysarthria progressing to anarthria (especially ALS2) — HPO: HP:0001260 (Dysarthria)
Dysphagia — HPO: HP:0002015
Pseudobulbar affect (ALS2) — HPO: HP:0000749

Gene-Specific Phenotype Summary

Table (click to expand)

Gene	Onset pattern	UMN/LMN balance	Bulbar/respiratory	Distinctive features
FUS	Median 21 yrs; often bulbar onset	Combined	Frequent, early	Myoclonic jerks, tremor, occasional cognitive/frontal decline
SETX (ALS4)	Mean ~16 yrs, slow	Balanced, distal-predominant LMN	Spared	Finger-to-nose dysmetria/ataxia in ~50%; sex-dependent penetrance
ALS2	Mean 4.9 yrs (1–20)	UMN-prominent early	Early, frequent (anarthria in 1st decade)	Pseudobulbar affect, scoliosis, preserved cognition
SIGMAR1	1–2 yrs	LMN (distal, forearm/hand)	Spared	Cognition preserved; overlaps distal HMN
SOD1 (JALS)	Late 2nd–early 3rd decade	Combined	Variable	Rapid, respiratory failure <2 yrs
SPTLC1	4–15 yrs	Mixed	Yes	Elevated serum ceramide
SPG11	7–23 yrs (2nd decade typical)	Balanced	Early/common	No cognitive impairment, no corpus callosum thinning (unlike HSP)
UBQLN2	16–24 yrs (rare juvenile cases)	Variable	Variable	Frontotemporal dementia common
(All PMID: 34946884)

Onset, Severity, Progression, Frequency

Age of onset: ranges from infancy (SIGMAR1, ALS2) through the third decade (SOD1, TARDBP), with the operational upper bound at 25 years.
Severity/progression: bimodal — rapidly fatal (FUS, SOD1: death from respiratory failure within 1–2 years) vs. slowly progressive over decades (SETX, ALS2, SPG11 [27–40 yr duration], UBQLN2 [~4 decades]) (PMID: 34946884).
Frequency of specific signs: quantitative frequency data are limited to small case series; e.g., SETX-ALS4 penetrance is markedly sex-skewed (31% of males vs. 13% of females symptomatic) (PMID: 34946884; Grunseich et al., Ann Neurol 2020, 10.1002/ana.25681).

Quality of Life

Disease-specific QoL instruments (EQ-5D, SF-36, ALSFRS-R-based QoL substudies) have been applied in adult ALS but are not reported as validated or systematically applied in pediatric/juvenile ALS in the literature surveyed. The functional impact is inferable from the clinical course: progressive loss of ambulation, speech, swallowing, and (in FUS/SOD1 forms) respiratory independence, with earlier and longer-duration disability in indolent forms (SETX, ALS2, SPG11) due to decades-long disease courses beginning in childhood/adolescence — a distinct QoL burden (loss of developmental milestones, prolonged pediatric-to-adult disability) compared with AO-ALS.

4. Genetic/Molecular Information

Causal Genes (detailed)

FUS (Fused in Sarcoma; RNA-binding protein) - Most common JALS gene; predominantly de novo heterozygous mutations, often clustered in the C-terminal nuclear localization signal (NLS) domain - P525L mutation: consistently associated with the most severe/earliest-onset form (median onset 21 yrs), higher bulbar involvement, shortest survival (Waibel et al., Neurology 2010, PMID: 20668260; Bäumer et al., PMID: 20668260) - De novo R503fs frameshift reported in a 17-year-old female with sporadic JALS, rapid course, death 15 months from onset (PMID: 32501131) - Y526C novel C-terminal mutation strengthens FUS as "the most frequent genetic factor in aggressive juvenile ALS" (PMID: 28054830) - FUS-P525L reported with intellectual disability and expanded phenotype (Neurol Genet 2024, 10.1212/NXG.0000000000200009) - Neuropathology: cytoplasmic basophilic inclusions in Betz cells of motor cortex, with 12–15 nm tubulofilamentous ultrastructure — distinct from the TDP-43 pathology of sporadic ALS (PMID: 34946884)

SETX (Senataxin; DNA/RNA helicase, ALS4) - Autosomal dominant, gain-of-function heterozygous mutations (chr 9q34); the only recurrent AD gene in JALS - Series of 31 patients: mean onset 16 years, slowly progressive, normal life span (PMID: 34946884; Grunseich 2020) - Allele-specific silencing of a dominant SETX mutation as a therapeutic strategy is under preclinical investigation (bioRxiv 2024, 10.1101/2024.10.11.617871) - SETX also causes the allelic disorder ataxia with oculomotor apraxia type 2 (AOA2, recessive), with ALS4 mutations occurring at distinct SETX protein locations from AOA2 mutations (PMID: 34946884)

ALS2 (Alsin; Rho guanine nucleotide exchange factor, chr 2q33) - Autosomal recessive; loss-of-function (often nonsense/frameshift, premature stop codon) mutations distributed across the gene with no hotspot - Encodes a ~180–185 kDa multidomain protein with three GEF domains for Rab5 and other small GTPases (PMID: 34946884) - Allelic spectrum: infantile-onset ascending hereditary spastic paralysis (IAHSP) → juvenile primary lateral sclerosis (JPLS) → juvenile ALS2, representing a phenotypic continuum of severity (PMC: 4180207; PMC: 8721836) - Novel splice-site ALS2 mutation reported establishing diagnosis in a family with early anarthria and generalized dystonia (PMC: 4256290)

SIGMAR1 (Sigma-1 receptor; ER chaperone, ALS16) - Autosomal recessive; onset 1–2 years; distal (forearm/hand) LMN-predominant, spared bulbar/respiratory function, preserved cognition - Also causes a distinct allelic phenotype, distal hereditary motor neuropathy (dHMN), without the rapid progression/widespread neurogenic damage typical of ALS (ScienceDaily 2011, link; PMID: 34946884; PMC: 6060428; PMC: 12041004)

SOD1 (Cu/Zn superoxide dismutase 1) - Only 3 reported JALS cases; predominantly de novo, distinct mutation spectrum and inheritance pattern from typical AO-ALS SOD1 (usually AD, mean onset 5th decade) - Rapid progression, death from respiratory failure <2 years; neuropathology shows anterior horn degeneration with Bunina bodies and gliosis (PMID: 34946884)

SPTLC1 (Serine palmitoyltransferase long-chain base subunit 1) - Mostly de novo (one AD family); onset 4–15 years; catalyzes the rate-limiting step of de novo sphingolipid synthesis; elevated serum ceramide (distinct from the elevated deoxysphingolipids seen in SPTLC1-associated HSAN) - One patient trialed serine supplementation, which produced weight gain but uncertain disease benefit and theoretical risk of worsening sphingolipid overproduction (PMID: 34946884)

SPG11 (Spatacsin) - Autosomal recessive; onset 7–23 years (2nd decade typical); "SPG11-ARJALS" clinically distinguished from SPG11-hereditary spastic paraplegia (HSP) by absence of cognitive impairment and absence of corpus callosum thinning on MRI (Orhan et al., Neurol Genet 2016, 10.1212/NXG.0000000000000025; PMID: 34946884)

UBQLN2 (Ubiquilin 2) - X-linked dominant; mutations cluster in the PXX domain; regulates ubiquitinated protein degradation; frequently associated with frontotemporal dementia (PMID: 34946884)

Other single-case/single-family genes: ERLIN1 (Turkish family, homozygous, ER lipid-raft protein), GNE (sialic acid synthesis), TARDBP (p.Gly348Val, one JALS case), VRK1 (kinase, with sensory neuropathy and intellectual deterioration), SYNE1 (nuclear envelope–actin linker), BICD2 (motor adaptor protein), DDHD1 (mitochondrial phospholipase) (all PMID: 34946884).

Variant Classification & Population Frequency

Systematic gnomAD/ClinVar-level population-frequency and ACMG/AMP classification data specific to JALS-causing variants were not comprehensively retrieved in this search; individual variants (e.g., FUS P525L, SETX L389S/R2136H) are reported as pathogenic/likely pathogenic in the primary literature and ClinGen curations (see ClinGen Gene-Disease Validity records for SETX/ALS4).

Somatic vs. Germline

All reported JALS-causing variants are germline (constitutional), including de novo germline events in FUS, SOD1, and SPTLC1 forms.

Functional Consequences

FUS: gain-of-toxic-function via cytoplasmic mislocalization, aberrant U1 snRNA interaction, and stress granule incorporation (see Section 6)
SETX: gain-of-function affecting R-loop resolution and TGF-β pathway activation
ALS2: loss-of-function (GEF activity loss) affecting Rab5-dependent endosomal trafficking
SIGMAR1: loss-of-function affecting ER chaperone activity

Epigenetic / Chromosomal Information

No JALS-specific epigenetic (DNA methylation/histone) or large-scale chromosomal abnormality (aneuploidy/translocation) mechanisms were identified in the literature surveyed; JALS is modeled as point mutation/small indel-driven monogenic disease.

5. Environmental Information

No JALS-specific environmental toxin, occupational, lifestyle, or infectious-agent risk factors were identified in the literature surveyed. This contrasts with adult sporadic ALS, where environmental epidemiology (e.g., military deployment, heavy metals, pesticides, β-N-methylamino-L-alanine/BMAA) is more extensively studied but still not disease-defining. No infectious trigger has been established for JALS. This represents a clear knowledge gap suitable for flagging as KNOWLEDGE_GAP in a curated entry.

6. Mechanism / Pathophysiology

Causal Chains by Gene

FUS pathway: De novo NLS-domain mutation → impaired nuclear import of FUS protein → cytoplasmic mislocalization of FUS in motor neurons → incorporation into stress granules (co-localizing with TIAR) and aberrant trapping of U1 snRNP biogenesis intermediates via aberrant Sm-site zinc-finger interaction with U1 snRNA → disrupted RNA metabolism/splicing and pathological stress-granule dynamics (shift to unstructured, AU-rich transcriptome) → dose-dependent gain of toxic function, RBP insolubility → progressive motor neuron loss (in FUS-P525L knock-in mice, ~30% lumbar motor neuron loss by 12 months and 37% NMJ denervation by 1 year) without obligate cytoplasmic aggregate formation → denervation, weakness, bulbar dysfunction, respiratory failure. Sources: Vance et al. (PMID: 20699327); Sun et al. (PMC: 7733473); PMC: 7705167; ALZFORUM hFUS-P525L model summary.

SETX (ALS4) pathway: Heterozygous gain-of-function SETX mutation (helicase domain, e.g., L389S, R2136H) → impaired DNA/RNA helicase function and R-loop resolution → genomic instability (altered Rad51 recruitment), dysregulated transcriptional termination, and TGF-β pathway activation → downstream TDP-43 nuclear clearing and cytoplasmic mislocalization in spinal motor neurons (both in knock-in mouse models and human ALS4 postmortem tissue) → nucleocytoplasmic transport dysfunction (Ran/RanGAP1 nuclear-membrane abnormalities, delayed nuclear import) and enhanced stress granule formation → autophagy dysregulation → slowly progressive distal LMN degeneration with UMN signs, sparing bulbar/respiratory neurons. Source: Bennett et al., Acta Neuropathol 2018, PMID: 29725819; PMID: 34946884.

ALS2 (alsin) pathway: Biallelic loss-of-function ALS2 mutation → loss of alsin GEF activity for Rab5 → impaired Rab5-dependent endosome fusion and macropinocytosis-associated trafficking → disturbed endosomal transport of IGF1 and BDNF receptors, excessive Rab5-positive vesicle accumulation, reduced endosomal motility and increased endosome-to-lysosome conversion → impaired trophic signaling and microtubule/actin cytoskeletal remodeling defects in corticospinal and lower motor neurons → retrograde degeneration of upper motor neurons of the pyramidal tract (predominant early), later LMN involvement → progressive spasticity, dysarthria/anarthria, slow disease course. Sources: Devon et al., PNAS 2006, 10.1073/pnas.0510197103; Deng et al., PMC: 2842444; PMC: 2364715; Molecular Brain 2009, link.

SIGMAR1 pathway: Loss-of-function mutation in the ER chaperone sigma-1 receptor → failure to prevent misfolded protein accumulation, and dysregulated lipid transport/ion channel regulation, particularly in motor neurons of brainstem/spinal cord (high SIGMAR1 expression sites) → distal LMN-predominant degeneration sparing bulbar/respiratory and cognitive function.

SPTLC1 pathway: Gain-of-function/altered-specificity mutation in the rate-limiting sphingolipid biosynthesis enzyme → elevated serum ceramide → lipotoxic stress in motor neurons → mixed UMN/LMN degeneration with early spasticity.

SPG11 (spatacsin) pathway: Biallelic loss-of-function → impaired cytoskeletal stability and synaptic vesicle transport regulation → distal LMN + UMN degeneration, early bulbar involvement, without the corpus callosum thinning/cognitive impairment characteristic of SPG11-HSP.

Cellular Processes & Biological Processes (GO term suggestions)

Endosomal transport/protein trafficking (GO:0016197 endosomal transport) — ALS2
Stress granule assembly (GO:0034063 stress granule assembly) — FUS
mRNA processing / U1 snRNP biogenesis (GO:0006397 mRNA processing; GO:0000387 spliceosomal snRNP assembly) — FUS
DNA damage response / R-loop resolution (GO:0000724 double-strand break repair via homologous recombination; GO:0061077 chaperone-mediated protein folding) — SETX
Nucleocytoplasmic transport (GO:0006913 nucleocytoplasmic transport) — SETX
Autophagy (GO:0006914 autophagy) — SETX, ALS2
Sphingolipid biosynthetic process (GO:0030148 sphingolipid biosynthetic process) — SPTLC1
ER protein quality control / chaperone activity (GO:0034975 protein folding in endoplasmic reticulum) — SIGMAR1
Protein ubiquitination/proteasomal degradation (GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process) — UBQLN2

Protein Dysfunction Modes

FUS: cytoplasmic mislocalization + gain of toxic function (no obligate aggregation required for toxicity in knock-in models)
SOD1: misfolding/aggregation, loss of antioxidant enzymatic function
ALS2/alsin: complete loss of GEF function (LOF)
SIGMAR1: loss of chaperone function (LOF)

Tissue Damage / Neurodegeneration Mechanisms

Motor neuron death via a combination of proteostatic stress, impaired axonal/vesicular transport, glial activation (astrocytosis and microgliosis observed in FUS-P525L mouse spinal cord), oxidative stress (rationale for edaravone), and secondary denervation of neuromuscular junctions.

Molecular Profiling

Transcriptomic/proteomic profiling of stress-granule composition in ALS-FUS models shows a shift to a more unstructured, AU-rich RNA content (Oxford NAR 2024, 10.1093/nar/gkad739). Broader multi-omic (single-cell, spatial transcriptomic) characterization specific to JALS tissue was not identified in this search and likely represents a gap given tissue scarcity in pediatric cases.

Suggested Cell Types (CL terms)

Upper motor neuron / Betz cell (CL:0011005 corticospinal neuron / betz cell terminology varies)
Lower motor neuron / spinal cord motor neuron (CL:0000100 motor neuron; CL:0011012 alpha motor neuron)
Astrocyte (CL:0000127) — reactive astrocytosis
Microglial cell (CL:0000129) — microgliosis

7. Anatomical Structures Affected

Organ/System Level

Primary: central nervous system — motor cortex (Betz cells/UMN), corticospinal tract, brainstem motor nuclei, spinal cord anterior horn (LMN) (UBERON:0002298 brainstem; UBERON:0002240 spinal cord; UBERON:0002771 femoral motor neuron / generic UBERON:0000010 peripheral nervous system for LMN axons)
Secondary: skeletal muscle (denervation atrophy; UBERON:0001134 skeletal muscle tissue), neuromuscular junction (UBERON:0031594), respiratory musculature (diaphragm — UBERON:0001103) in aggressive forms (FUS, SOD1)
Body systems: nervous system (primary), musculoskeletal system (secondary — scoliosis in ALS2, contractures), respiratory system (bulbar/respiratory forms)

Tissue/Cell Level

Corticospinal (upper) motor neurons of the motor cortex
Spinal/bulbar (lower) motor neurons
Reactive astrocytes and microglia in affected spinal cord segments

Subcellular Level (GO Cellular Component)

Nucleus/nuclear pore complex (FUS mislocalization, SETX nucleocytoplasmic transport defect) — GO:0005634, GO:0005643
Cytoplasmic stress granules — GO:0010494
Endosomes/Rab5-positive vesicles (ALS2) — GO:0005768
Endoplasmic reticulum (SIGMAR1 chaperone) — GO:0005783
Mitochondria (DDHD1 phospholipase regulation) — GO:0005739

Localization/Lateralization

JALS motor neuron degeneration is typically symmetric/bilateral; asymmetric onset is reported in some SOD1-JALS cases. Imaging correlates: FUS shows T2/FLAIR pyramidal tract hyperintensity plus frontal atrophy/hypoperfusion; ALS2 shows mild cortical atrophy and corticospinal tract thinning; SYNE1 shows mild cerebellar atrophy (PMID: 34946884).

8. Temporal Development

Onset

Congenital/infantile: SIGMAR1 (1–2 yrs)
Early childhood: ALS2 (mean 4.9 yrs, range 1–20)
Childhood/adolescent (first–second decade): SETX (mean 16), SPTLC1 (4–15), SPG11 (7–23, typically 2nd decade), SYNE1 (11–12), ERLIN1 (before 24 in 6/12 family members)
Late second/third decade: FUS (median 21), SOD1 (late 2nd–early 3rd decade), GNE (mean 26, range 12–35), TARDBP (24), UBQLN2 (16–24) Onset is typically insidious, with symptom progression over months before diagnosis rather than acute presentation (PMID: 34946884).

Progression

Rapid (1–2 year mortality): FUS, SOD1
Intermediate (1–2 decades): GNE (mean 13.4 yrs), SYNE1 (death ~age 39)
Slow (multiple decades, near-normal lifespan possible): SETX/ALS4 ("normal life span" per OMIM #602433), ALS2, SIGMAR1, SPTLC1, SPG11 (27–40 yr disease duration), UBQLN2 (~4 decades), ERLIN1 (death 5th–6th decade) (PMID: 34946884)

Patterns

No spontaneous remission is described for JALS. "Critical periods" are not formally defined, though the operational <25-year onset window itself demarcates the diagnostic category. Disease course is generally monophasic progressive rather than relapsing-remitting, distinguishing JALS from its phenocopies (e.g., HSP, which can show more static/slowly progressive UMN-only courses).

9. Inheritance and Population

Epidemiology

US National ALS Registry (2010–2018): 44 confirmed/likely juvenile ALS cases (onset <25 yrs) identified nationally; age-adjusted prevalence rose from 0.21/100,000 (2015) to 0.24/100,000 (2018) (Larkin et al. 2023, PMID: 37789566)
Overall ALS prevalence (all ages, US) is ~9.9 per 100,000 for context; only ~5% of all ALS cases have onset before age 30, and ~13% before age 40 (Target ALS summary; general ALS epidemiology literature)
Demographics from the registry: 79.5% male / 20.5% female (>3:1 male predominance); 54.5% non-white / 45.5% non-Hispanic white — an "inverse" pattern relative to general ALS demographics (which skew white); geographic distribution: Northeast 29.5%, Midwest 25%, South/West 15.9% each (PMID: 37789566)

Inheritance Patterns (genetic forms)

Table (click to expand)

Gene	Inheritance
ALS2, SIGMAR1, SPG11, ERLIN1, GNE, VRK1	Autosomal recessive
SETX	Autosomal dominant (only recurrent AD gene)
FUS, SOD1, SPTLC1 (most)	De novo (dominant, non-inherited)
UBQLN2	X-linked dominant
(PMID: 34946884)

Penetrance / Expressivity

SETX-ALS4 shows incomplete, sex-dependent penetrance — males symptomatic 31% vs. females 13%, with males also showing greater disease burden and higher serum creatine kinase (PMID: 34946884; Grunseich 2020, 10.1002/ana.25681). Variable expressivity is evident across the phenotypic continuum of ALS2 mutations (IAHSP–JPLS–JALS2).

Genetic Anticipation, Mosaicism, Founder Effects

Not systematically documented for JALS in the literature surveyed. ALS2 was historically over-represented in consanguineous North African and Middle Eastern families, consistent with a founder/consanguinity effect for autosomal recessive disease, though the gene is now recognized globally (PMID: 34946884).

Consanguinity

Elevated relevance for the autosomal recessive forms (ALS2, SIGMAR1, SPG11) given their original ascertainment in consanguineous pedigrees.

Carrier Frequency

Population carrier-frequency data (gnomAD-derived) specific to JALS-causing recessive alleles were not retrieved in this search and would need dedicated gnomAD querying per gene/variant.

10. Diagnostics

Clinical Criteria

JALS diagnosis rests on: (1) age of onset <25 years, and (2) evidence of combined UMN + LMN degeneration, applying the same clinical framework used for AO-ALS (revised El Escorial / Awaji criteria), which have recognized limitations in sensitivity, particularly in atypical/pediatric presentations (search results on El Escorial criteria, 2024–2025 literature). The principal JALS review states: "Patients presenting with combined upper and lower motor neuron disorders before age 25 should be carefully examined for genetic mutations" (PMID: 34946884).

Electrodiagnostics (EMG/NCS)

Pattern across JALS genes: active denervation with chronic neurogenic changes and no sensory abnormalities on nerve conduction studies (consistent with a pure motor neuronopathy), though it "confirms LMN involvement but [is] not useful in distinguishing the different gene mutations." SETX is a partial exception, showing low/absent motor NCS amplitudes with normal sensory studies (PMID: 34946884).

Imaging

MRI often normal or shows only mild abnormality
FUS: pyramidal tract T2/FLAIR hyperintensity, frontal atrophy/hypoperfusion
ALS2: mild cortical atrophy, corticospinal tract thinning
SETX: muscle MRI shows distal lower-extremity fatty infiltration
SYNE1: mild cerebellar atrophy (PMID: 34946884)

Genetic Testing

Given the 40% genetic yield, multigene panel testing (or WES) covering ALS2, SETX, FUS, SIGMAR1, SOD1, SPTLC1, SPG11, UBQLN2, and the rarer genes is the recommended diagnostic approach once combined UMN/LMN signs with onset <25 years are established. Single-gene testing may be prioritized by phenotype (e.g., SETX first for AD family history with distal, bulbar-sparing disease; ALS2 for AR consanguineous families with very early anarthria/spasticity).

Differential Diagnosis ("JALS mimics")

Juvenile Primary Lateral Sclerosis (JPLS): UMN-only, ALS2-associated
Hereditary Spastic Paraplegia (HSP): UMN-predominant, sensory neuropathy, no bulbar involvement typically; SPG11, ALS2, ERLIN1, DDHD1-associated; MRI corpus callosum thinning (contrasting with SPG11-ARJALS)
Spinal muscular atrophy (SMA): pure LMN, no UMN signs — the key discriminator per differential-diagnosis literature
Distal hereditary motor neuropathy (dHMN): LMN-only (SIGMAR1 allelic overlap)
NBIA (neurodegeneration with brain iron accumulation): reported mimicking JALS initially in one case (10-year-old girl) before basal ganglia iron deposition emerged (PMID: 34946884)

11. Outcome/Prognosis

Survival/Mortality

Prognosis is strongly gene-dependent rather than uniform: - Poor prognosis / rapid mortality: FUS (death from respiratory failure within 1–2 years, especially P525L), SOD1-JALS (documented deaths <2 years) - Favorable/near-normal prognosis: SETX/ALS4 (OMIM: "normal life span"), ALS2 (slow progression despite early onset), SPG11 (27–40 year disease duration), UBQLN2 (~4-decade course) (PMID: 34946884)

Morbidity/Functional Outcomes

Long-duration forms (ALS2, SETX, SPG11) accrue substantial cumulative disability (progressive spasticity, anarthria, loss of ambulation) over a period spanning childhood through adulthood — a distinct morbidity profile from AO-ALS's shorter but more uniformly fatal course.

Prognostic Factors

The causative gene is itself the dominant prognostic factor; the review states, "hereditary patterns and coexisting features may be useful in determining prognosis," and that gene identification "allows for a better prediction of prognosis and early diagnostic testing in other affected family members" (PMID: 34946884). No validated biomarker-based prognostic score specific to JALS was identified (contrast with AO-ALS, where plasma neurofilament light chain (NfL) is an emerging prognostic/pharmacodynamic biomarker, notably used in tofersen trials).

12. Treatment

Pharmacotherapy

Riluzole — the only agent broadly used across ALS with proven (modest) survival benefit in adults (2–3 month prolongation of tracheostomy-free survival); pediatric/juvenile use is described in the literature as "less established," used at some centers on a case-by-case basis (Healthline; NCBI Bookshelf review; PMID search results)
Edaravone — FDA-approved 2017 for AO-ALS (antioxidant, reduces oxidative/free-radical injury); pediatric investigation described as ongoing/limited, with regional variation in approval status
Tofersen (antisense oligonucleotide) — FDA accelerated approval April 2023, specifically for SOD1-mutant ALS; intrathecally administered, binds SOD1 mRNA to reduce toxic SOD1 protein and CSF SOD1 levels; reduces plasma neurofilament light chain, though ALSFRS-R functional benefit has been variable across trials (NEJM 2022, PMID: [35379992]; systematic review PMC: 12003547). Given SOD1's rarity as a JALS cause (3 reported cases) but its druggability, this is the clearest example of a genotype-matched precision therapy potentially applicable to a JALS subgroup, though pediatric/juvenile-specific trial data were not identified in this search.
Serine supplementation (SPTLC1) — trialed in one SPTLC1-JALS patient, produced weight gain; "utility... is uncertain and may potentially worsen the overproduction of sphingolipids" (PMID: 34946884)

Advanced/Experimental Therapeutics

Antisense oligonucleotide silencing approaches are in preclinical development for FUS (PMC: 8799464) and for the dominant SETX ALS4 mutation via allele-specific silencing (bioRxiv 2024)
Gene therapy trials (e.g., NCT04632225, "Engensis"/VM202) are registered for ALS broadly but not JALS-specific

Supportive/Rehabilitative Care

Multidisciplinary clinic management (neurology, pulmonology, PT/OT, speech-language pathology, nutrition, social work, ALS association support) is standard of care; respiratory support ranges from noninvasive to invasive mechanical ventilation as disease progresses (search results, general ALS management literature; NCIT:C15302 Physical Therapy, NCIT:C15315 Rehabilitation, NCIT:C15747 Supportive Care).

Treatment Algorithm Notes

No JALS-specific clinical practice guideline algorithm was identified; management is extrapolated from AO-ALS guidelines with genotype-informed personalization emphasized as the field's stated future direction: "With the future of personalized medicine, the identification of a disease-causing gene mutation may lead to treatment" (PMID: 34946884).

Suggested NCIT terms: NCIT:C15986 (Pharmacotherapy) for riluzole/edaravone; NCIT:C15238 (Gene Therapy) for ASO approaches (tofersen, investigational FUS/SETX ASOs); NCIT:C15240 (Genetic Counseling); NCIT:C15315 (Rehabilitation); NCIT:C15313 not applicable (no radiotherapy role).

13. Prevention

Primary/Secondary Prevention

No primary prevention strategy exists (genetic, non-modifiable causal factors dominate). Secondary prevention centers on genetic counseling and cascade family testing once a proband's causative variant is identified, given that gene identification "allows for... early diagnostic testing in other affected family members" (PMID: 34946884).

Screening

No population-based newborn or carrier screening program specific to JALS genes was identified.
For autosomal recessive forms (ALS2, SIGMAR1, SPG11) in populations with known consanguinity/founder variants, targeted carrier screening and prenatal/preimplantation genetic testing would be a plausible clinical application, though not documented as an established program in the literature surveyed.

Genetic Counseling

Recommended for families with a confirmed pathogenic variant, particularly for the autosomal dominant (SETX) and X-linked (UBQLN2) forms where risk to relatives is high and predictable, and for autosomal recessive forms where carrier status and reproductive risk counseling is relevant.

Public Health / Prophylaxis

Not applicable — no infectious or environmentally preventable component has been established for JALS.

14. Other Species / Natural Disease

No naturally occurring juvenile-onset ALS phenocopy in non-human species was identified in this search. (Note: dismech's existing Amyotrophic_Lateral_Sclerosis entry documents naturally occurring canine degenerative myelopathy [SOD1 E40K homozygous dogs] as an adult/older-onset model informative for general ALS motor neuron degeneration — PMID:19188595 — but this is not described as a juvenile-onset natural disease analog and would need independent verification before being cited under a JALS-specific entry.) Comparative/orthologous gene information (ALS2, SETX, FUS, SOD1 orthologs) is well established across model organisms per Alliance of Genome Resources/MGI/RGD but was not separately queried here.

15. Model Organisms

Mouse Models

Als2−/− (alsin knockout) mice: Decreased locomotor activity, small but significant decrease in cortical motor neuron size; "four ALS2-deficient mouse models have been generated by different groups... though these mouse models largely fail to recapitulate hallmarks of motor neuron disease" — i.e., fidelity is LOW/MODERATE and should be flagged as a HUMAN_MODEL_MISMATCH in curation. Mechanistically, Als2−/− neurons show disturbed Rab5-dependent endosomal transport of IGF1/BDNF receptors, excess Rab5-positive vesicle accumulation, reduced endosomal motility (Devon et al., PNAS 2006, 10.1073/pnas.0510197103; PMC: 2364715). Als2 loss also exacerbates motor dysfunction when crossed onto a SOD1-H46R AO-ALS mouse background, via disturbed endolysosomal trafficking (Deng et al., PMC: 2842444) — a genetic-modifier/epistasis model rather than a standalone JALS model.
SETX knock-in mice (L389S and R2136H): Both transgenic and knock-in approaches yield mice with neuromuscular phenotypes and motor neuron degeneration; critically, they recapitulate TDP-43 nuclear clearing and cytoplasmic mislocalization, matching human ALS4 postmortem spinal cord pathology — a relatively high-fidelity model for the TDP-43 pathology arm, with additional readouts of nucleocytoplasmic transport dysfunction (Ran/RanGAP1 abnormalities) and enhanced stress granule formation (Bennett et al., Acta Neuropathol 2018, PMID: 29725819).
FUS-P525L humanized knock-in mice ("hFUS-P525L"): Progressive, age-dependent lumbar motor neuron loss (~30% by 12 months), NMJ denervation (37% loss of tibialis NMJs by 1 year), astrocytosis/microgliosis, occurring via a dose-dependent gain-of-toxic-function mechanism without obligate cytoplasmic aggregation — an important negative/nuanced finding: "the ALS FUS knock-in model... showed neuronal dysfunction and degeneration in the absence of cytoplasmic FUS protein accumulation, suggesting aggregates may not be the initial drivers of neuronal dysfunction" (ALZFORUM hFUS-P525L summary; related "FUSΔ14" knock-in model, PMC: 5841203).

Other Model Systems

C. elegans FUS knock-in models show disrupted autophagy and neuronal dysfunction (bioRxiv, 10.1101/799932)
A separate TDP-43 knock-in mouse model (independent of SETX) is described as "a robust TDP-43 knock-in mouse model of ALS" relevant to the broader TDP-43 proteinopathy shared across ALS subtypes (PMC: 6975031)
iPSC-derived motor neurons: a human iPSC line carrying a de novo pathogenic FUS mutation identified in a juvenile ALS patient was differentiated into motor neurons showing pathological characteristics recapitulating patient disease features (PMC: 7507938) — a patient-derived cellular model with inherently high genotype fidelity.

Model Limitations Summary

Across all mouse models, a recurring limitation is that rodent lifespan/physiology compresses or alters the decades-long human juvenile disease course, and that Als2 knockout mice in particular fail to fully recapitulate the human motor neuron disease phenotype despite the biochemical (endosomal trafficking) defect being conserved — an explicit candidate for a HUMAN_MODEL_MISMATCH discussion node in any curated pathophysiology entry.

Summary of Key Evidence Gaps

Environmental risk/protective factors for JALS are essentially unstudied as a distinct question from AO-ALS.
Population genetics (gnomAD carrier frequencies, penetrance estimates) for most JALS genes beyond SETX are not well quantified.
JALS-specific treatment trial data (riluzole/edaravone/tofersen efficacy in patients <25 years) are sparse; most evidence is extrapolated from adult trials or single case reports.
Quality-of-life instruments validated specifically for pediatric/juvenile ALS were not identified.
Als2 mouse models' translational fidelity is explicitly reported as poor, an important caveat for any pathophysiology narrative built on this model.

Sources

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Table (click to expand)

Outcome	Count
References checked	37
Resolved	37
Unresolved (possible confabulation)	0
Unverifiable	0
Quoted claims checked	7
Quoted claims found in source	4
Quoted claims not found in source	3
References weighed for topical relevance	37
On topic	23
Off topic	0

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

2 of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

PMID:28054830 (abstract only): "the most frequent genetic factor in aggressive juvenile ALS"
closest text in source: "Although amyotrophic lateral sclerosis (ALS) typically occurs around 60 years, numerous publications report an onset of ALS before the age of 25 years that define juvenile ALS (jALS)"
PMID:34946884: "utility... is uncertain and may potentially worsen the overproduction of sphingolipids"
closest text in source: "Treatment with serine was initiated in one patient and resulted in weight gain, [57] although the utility of this approach is uncertain and may potentially worsen the overproduction of spingolipids [58]"
PMC:PMC5841203 (abstract only): "the ALS FUS knock-in model... showed neuronal dysfunction and degeneration in the absence of cytoplasmic FUS protein accumulation, suggesting aggregates may not be the initial drivers of neuronal dysfunction"
closest text in source: "Using our new FUSDelta14 ALS mouse-antibody system we show that neurodegeneration occurs in the absence of FUS protein aggregation"